From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As a key global platform in hematology, the meeting focused on advances in hematopoietic stem cell transplantation, cellular immunotherapy, and complication management.

At this year's congress, GoBroad Healthcare Group presented a total of 20 research studies, including 3 oral presentations and 17 poster sessions, highlighting the team's systematic exploration in the full-process management of stem cell transplantation and cellular therapy.

In the oral session, the team addressed several key clinical challenges, including the use of autologous stem cell transplantation combined with CAR-T therapy in relapsed/refractory central nervous system lymphoma, the effectiveness and safety of belumosudil in pediatric chronic graft-versus-host disease, and the use of dual-target CAR-T therapy as a salvage strategy in lupus nephritis. These studies reflect innovative approaches in managing complex diseases.

Poster presentations further covered areas such as optimization of CAR-T combined transplantation strategies, mechanisms of relapse and resistance, dynamic biomarker monitoring, and transplant-related complication management, providing new evidence to improve treatment precision and safety.

The presentation of these studies at EBMT 2026 demonstrates GoBroad Healthcare Group's continued commitment to advancing clinical research and translating findings into practical treatment strategies. By focusing on real-world clinical needs, the team aims to deliver safer and more durable outcomes for patients with hematologic diseases.

Looking ahead, GoBroad Healthcare Group will continue to deepen clinical research, strengthen international collaboration, and contribute to the advancement of hematologic care. Further updates from EBMT 2026 will be shared in the coming days.